Trevi Therapeutics, Inc. (TRVI)

2,7800 +0,2400 (+9,45%) Alla chiusura: 04:00PM EDT

Trevi Therapeutics, Inc.

195 Church Street
16th Floor
New Haven, CT 06510
United States
203-304-2499
https://www.trevitherapeutics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 25

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Jennifer L. Good	Co-Founder, CEO, President & Director	781,85k	N/D	1965
Dr. Thomas R. Sciascia M.D.	Co-Founder & Chief Science Officer	530,48k	N/D	1953
Dr. David J. Clark A.F.P.M., M.D., M.R.C.P.	Chief Medical Officer	325,39k	N/D	1965
Ms. Lisa Delfini	Chief Financial Officer	N/D	N/D	1970
Mr. Christopher Galletta	Controller & Chief Accounting Officer	N/D	N/D	1978
Katie McManus	Communications Manager	N/D	N/D	N/D
Mr. Farrell Simon Pharm.D.	Chief Commercial Officer	N/D	N/D	N/D
Ms. Danine Summers	Vice President of Medical Affairs	N/D	N/D	1958

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Governance aziendale

L'ISS Governance QualityScore di Trevi Therapeutics, Inc. al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.